Krakow, Poland, March 31, 2015 / B3C newswire / -- Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, announced today that it is commencing IND-enabling studies for SEL24 project, the company’s first oncology drug candidate.
SEL24 is a novel, orally-available small molecule, selective inhibitor of PIM and FLT3 kinases, with potential application in the treatment of acute myeloid leukemia (AML), non-Hodgkin’s lymphoma, multiple myeloma and other neoplastic disorders. SEL24 compound has shown significant activity in multiple hematological xenograft models as a single agent and has demonstrated synergistic effects with marketed standard of care compounds and therapies in advanced clinical development, such as cytarabine. The compound has also favorable therapeutic window in non-GLP toxicology studies. These Investigational New Drug (IND) enabling studies are integral to the submission of the application for First-In-Humans (FIH) clinical trials.
On March 31st, Selvita signed a service agreement with Aptuit, the leader in early to mid-phase drug development support, for the preparation of selected studies for the IND/CTA data package. This includes both the regulatory and GLP (Good Laboratory Practice) toxicology and safety pharmacology testing in rodents and dogs, as well as large-scale GMP (Good Manufacturing Practice) synthesis of the test compound.
“Initiation of the IND-Enabling Studies is a major milestone in our development of SEL24 and Selvita”, said Dr. Krzysztof Brzozka, Chief Scientific Officer at Selvita. “We are very excited to be at this point, the last step before Phase I clinical trials, when we’ll be able to offer a potentially breakthrough treatment to oncohematology patients”, he added.
Dr. Jonathan Goldman MD, Chief Executive Officer at Aptuit added: “Aptuit is a leading provider of integrated IND enabling development programs. We are delighted to support Selvita at this time with our expert scientists and world class GMP and GLP capabilities”.
Selvita expects to incur also other costs related to SEL24 pre-clinical development in addition to the contract with Aptuit.
About Aptuit
Aptuit is a pharmaceutical services company that delivers early discovery to mid-phase drug development solutions by applying scientific excellence, outstanding service and a team of some of the foremost scientific professionals in the industry. The company has multiple sites both in US and Europe. Aptuit has significant experience and expertise in the oncology disease area, in both hematologic and solid tumors, and multiple mechanisms of action, including tyrosine-kinase inhibitors. More info: www.aptuit.com
About Selvita
Selvita is a drug discovery company founded in 2007 in Krakow, Poland. The company offers drug discovery support at every stage of the early discovery phase up to the preclinical research. Currently Selvita employs 225 scientists, including 75 PhDs, with extensive experience in area of life sciences. Selvita's laboratories possess the GLP and GMP certification. Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. Selvita also develops proprietary research programs primarily in the area of oncology. Selvita offices are located in Greater Boston Area and Krakow, Poland, and the company is listed on the Main Market of Warsaw Stock Exchange (WSE:SLV).
Contact
Natalia Baranowska
This email address is being protected from spambots. You need JavaScript enabled to view it.
+48 784 069 418